【摘 要】
：
Objective To investigate the risk factors of cerebral microbleeds(CMBs) in patients with acute ischemic stroke.Methods One hundred and thirty one patients with ischemic stroke who were hospitalized in
【机 构】
：
Ningxia Medical University;Depatment of neurology,General Hospital of Ningxia Medical University
论文部分内容阅读
Objective To investigate the risk factors of cerebral microbleeds(CMBs) in patients with acute ischemic stroke.Methods One hundred and thirty one patients with ischemic stroke who were hospitalized in Department of Neurology of General Hospital of Ningxia Medical University from November 2012 to June 2013 were successionally recruited.
其他文献
目的 华法林主要用于血栓栓塞疾病.临床常以国际标准化比值(international normalized ratio,INR)作为其抗凝监测指标,不同治疗目的有不同目标INR值.当脑栓塞后二级预防需将INR控制在2.0～3.0时,国人的华法林维持剂量约在3.0mg.我们遇到1例需要高剂量及对华法林不同品种敏感性有差异的患者,报道如下并做相关文献复习.以提高脑栓塞后抗凝治疗的规范性.
背景与目的 大脑中动脉主干梗死是脑梗死中比较严重的类型,相应脑组织损害范围大,临床表现上除了梗死部位相应的神经功能缺损外,还伴有意识障碍,颅内压增高,病情进展快且危重,死亡率远超过25％.本文采用随机、对照试验的方法以常规治疗患者为对照,观察纳美芬对大脑中动脉主干脑梗死患者的神经功能恢复作用.通过对给药前后患者的格拉斯哥昏迷评分(GCS)、美国国立卫生院神经功能缺损评分(NIHSS)及血清中基质金
Background Considering potential risk of hemorrhage and following poor clinical outcome after intravenous thrombolytic therapy in acute ischemic stroke patients,identifying high-risk patients before t
目的 比较人尿激肽原酶(尤瑞克林)治疗进展性卒中患者前、后循环梗死的临床疗效.方法 按英国牛津郡卒中研究分型(OSCP)将108例进展性卒中患者分为两组,前循环梗死69例、后循环梗死39例.再分别对前、后循环脑梗死患者分为两组,对照组(针对不同发病机制给予抗凝、抗血小板聚集和他汀类药物等治疗)和治疗组(除常规治疗外,静脉滴注尤瑞克林0.15 U/d),以14d为一个疗程,治疗前后行神经功能缺损评分
Although tongxinluo is a well-known traditional Chinese medicine complex that has been widely used for the treatment of cardiovascular and cerebrovascular diseases in China and has recently been ident
Background and Purpose Atherosclerosis is an important causative factor of ischemic stroke.For those patients who have intracranial angiostenosis with over 60％ occlusion,intravascular stenting has alw
目的 了解不同剂量rt-PA静脉溶栓治疗急性超早期脑梗死的有效性及安全性.方法 本研究分析自201 2年4月至201 3年1 1月间在我院神经内科溶栓治疗急性脑梗死患者,其中研究组33例(rt-PA0.6mg/kg),对照组29例(rt-PA0.9mg/kg),溶栓后给予改善微循环、营养神经药物.按时评定神经功能缺损.采用:1.美国国立卫生研究院卒中量表(NIHSS)评定溶栓前、24h及第3天时神
Background A recombinant tissue plasminogen activator (tPA),alteplase,was approved for patients with acute ischemic stroke within 3h of onset in Japan in October 2005 at a dose of 0.6 mg/kg.The aim of
目的 观察前列地尔脂微球载体制剂(Lipo-PGE1)对急性脑梗死患者神经功能缺损的改善情况,并应用单光子发射计算机断层成像术(SPECT)观察其选择性改善病变区脑血流量的情况以及是否会引起脑内盗血现象.方法 将60例急性脑梗死患者随机分为对照组(n=30)和治疗组(n=30),对照组应用阿司匹林+依达拉奉的基础治疗以及对症支持治疗,2周为一个疗程.治疗组在对照组的基础治疗上,应用前列地尔脂微球载
Ischemic neuronal cell apoptosis is a principal neuropathological feature of stroke.The p75 neurotrophin receptor (p75NTR) induce apoptosis associated with JNK-p53-BAX pathway,p53 is the substrate of